Soligenix climbs on European patent for key ingredient in blood cancer therapy
Brief: Soligenix May Sell Shares Of Common Stock Of Up To $5.8 Mln
Soligenix jumps on positive interim data from late-stage cancer therapy trial
Brief: Soligenix Announces Positive Clinical Results From A Comparative Study
Brief: Soligenix Announces Reverse Stock Split
Brief: Soligenix In Compliance With Nasdaq Stock Market's Requirement
Soligenix Inc reports results for the quarter ended in January - Earnings Summary
Soligenix Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Soligenix Extends Patent Protection For Its Filovirus Vaccine Platform To The United Kingdom And South Africa
Brief: FDA Grants Soligenix Orphan Drug Designation For The Prevention And Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Brief: Soligenix Announces Agreement On Design Of Second Confirmatory Placebo-Controlled Trial For HyBryte With European Medicines Agency
Brief: Soligenix Announces Recent Accomplishments And Year End 2023 Financial Results
Brief: Soligenix Announces Formation Of Behçet's Disease Medical Advisory Board
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma
Soligenix up as FDA grants "fast track" tag to inflammatory disease drug
U.S. STOCKS ON THE MOVE-Crypto stocks, US insurers, EPAM Systems
U.S. STOCKS ON THE MOVE-Apple, Lamb Weston, Dyne Therapeutics